Search results for "Erythropoietin derivative"

showing 2 items of 2 documents

Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.

2009

OBJECTIVE: Intracerebral hemorrhage (ICH) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its long-lasting analog, darbepoetin alfa, have been demonstrated to be neuroprotective in several models of neuronal insult. The objectives of this study were to analyze whether the systemic administration of recombinant human EPO (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery and brain damage in a rat model of ICH. METHODS: Experimental ICH was induced in rats by injecting autologous blood into the right striatum under stereotactic guidance. Subsequently, animal…

Brain InfarctionMaleDarbepoetin alfaBrain EdemaBrain damageNeuroprotectionDrug Administration ScheduleCentral nervous system diseaseRats Sprague-DawleyBlood Transfusion AutologousErythropoietin; Erythropoietin derivative; Intracerebral hemorrhage; Neuroprotectionhemic and lymphatic diseasesEdemamedicineAnimalsHumansDarbepoetin alfaErythropoietinCerebral HemorrhageIntracerebral hemorrhagebusiness.industryBasal Ganglia HemorrhageBrainmedicine.diseaseNeuroprotectionCorpus StriatumRecombinant ProteinsRatsErythropoietin derivativeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeErythropoietinAnesthesiaErythropoietin Erythropoietin derivative Intracerebral hemorrhage NeuroprotectionSystemic administrationHematinicsSurgeryNeurology (clinical)medicine.symptomIntracerebral hemorrhagebusinessmedicine.drugNeurosurgery
researchProduct

Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic

2004

Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype–selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to the classical EPO receptor (EPOR) and did not show any hematopoietic activity in human cell signaling assays or upon chronic dosing in different animal species. Nevertheless, CEPO and various nonhematopoietic mutants were cytoprotective in vitro and conferred neuroprotection against stroke, spinal cord compression, diabetic neuropathy, and experimental autoimmune encephalomyeli…

Encephalomyelitis Autoimmune ExperimentalEncephalomyelitiscarbamylated erythropoietinApoptosisPharmacologyLigandsNeuroprotectionRats Sprague-DawleyMiceStructure-Activity RelationshipDiabetic Neuropathiesddc:570hemic and lymphatic diseasesReceptors ErythropoietinmedicineAnimalsHumansErythropoiesisReceptorErythropoietinCells CulturedNeuronsMice Inbred C3HBinding SitesMultidisciplinaryChemistryExperimental autoimmune encephalomyelitisErythropoietin; erythropoietin receptor; carbamylated erythropoietin; neuroprotective agentsmedicine.diseaseRecombinant ProteinsRatsErythropoietin receptorStrokeNeuroprotective AgentsErythropoietin Erythropoietin derivative NeuroprotectionHematocritMutagenesisErythropoietinDrug DesignImmunologyErythropoiesisFemaleNervous System DiseasesSignal transductionerythropoietin receptorSpinal Cord CompressionSignal Transductionmedicine.drugScience
researchProduct